Merck to Present New Data on TROP2 ADC Sacituzumab Tirumotecan and Other Oncology Pipeline Candidates at ASCO 2024
MSD
Pharmaceutical R&D and Manufacturer
MSD to Present New Data at the 2024 ASCO Annual Meeting, Showcasing Advances in Innovative Therapies from a Broad Product Portfolio and Diverse Pipeline
New data from a Phase III study of the investigational TROP2 antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) released, evaluating its use in previously treated locally recurrent or metastatic triple-negative breast cancer.
First Release of Three-Year Follow-Up Data from a Phase IIb Study of mRNA-4157 (V940), an Investigational Personalized Neoantigen Therapy, in Combination with Pembrolizumab for High-Risk Stage III/IV Melanoma After Complete Resection
Rahway, New Jersey, USA, May 15, 2024 – MSD (the corporate name of Merck & Co., Inc. in Rahway, New Jersey, USA) announced that the company will present research data involving more than 25 different types of cancer from its portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, USA, from May 31 to June 4, further demonstrating MSD's ongoing progress in advancing clinical research.
Regarding Pembrolizumab, key data releases include updated and long-term follow-up data for certain advanced gastric cancer and advanced melanoma, as well as new quality of life and patient-reported outcome data for metastatic bladder cancer and early-stage non-small cell lung cancer.
Key data on pembrolizumab to be presented at the ASCO meeting include:
Three-Year Follow-Up Data from the Phase III KEYNOTE-966 Study Evaluating Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients with Advanced Biliary Tract Cancer (BTC) (Abstract #4093; Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Poster Session)
Longer-term Follow-up Data from the Phase III KEYNOTE-859 Study Evaluating Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone for HER2-Negative Gastric or Gastroesophageal Junction Cancer (Abstract #4045; Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Poster Session)
Patient-Reported Outcomes (PROs) Data from the Phase III KEYNOTE-A39/EV-302 Study: Evaluation of Pembrolizumab Plus Enfortumab Vedotin Versus Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) (Abstract #4502; Genitourinary Cancer—Kidney and Bladder Oral Abstract Session)
Phase III KEYNOTE-671 Study Health-Related Quality of Life (HRQoL) Data: Evaluation of Pembrolizumab in the Perioperative Setting (Neoadjuvant Pembrolizumab Plus Chemotherapy, Followed by Adjuvant Pembrolizumab Monotherapy Post-Surgery) Versus Preoperative Chemotherapy for Resectable Stage II, IIIA, and IIIB Non-Small Cell Lung Cancer (Abstract #8012; Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Rapid Oral Abstract Session)
Updated Efficacy and Safety Data from Two Cohorts of the Phase II KEYNOTE-224 Study: Evaluation of Pembrolizumab Monotherapy in Sorafenib-Treated and Previously Untreated Advanced Hepatocellular Carcinoma (HCC) Patients (Abstract #4100; Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Poster Session)
Long-term data from the Phase II KEYNOTE-629 study evaluating pembrolizumab for recurrent/metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) not curable by surgery or radiation (Abstract #9554; Melanoma/Skin Cancers Poster Session)
MSD Continues to Build a Broad Portfolio in the Oncology Field, to Present Data from Its Diverse R&D Pipeline at ASCO, Including Multiple Studies Evaluating Combination Data with Pembrolizumab, Such as the Investigational Personalized Neoantigen Therapy (INT) mRNA-4157 (V940) in Collaboration with Moderna; the Investigational Compound Vibostolimab/Pembrolizumab, an Anti-TIGIT Therapy; the Investigational TROP2-Targeted Antibody-Drug Conjugate (ADC) Sacituzumab Tirumotecan (Sac-TMT, formerly known as MK-2870/SKB264) Co-developed with Kelun-Biotech; and the Investigational HER3-Targeted ADC Patritumab Deruxtecan (HER3-DXd) Co-developed with Daiichi Sankyo.
Key abstracts of the R&D pipeline presented at the ASCO meeting include:
Three-Year Follow-Up Data from the Phase IIb KEYNOTE-942/mRNA-4157-P201 Study Released for the First Time, Evaluating mRNA-4157 (V940) in Combination with Pembrolizumab for Adjuvant Treatment of High-Risk Melanoma After Complete Resection (Abstract #LBA9512; Melanoma/Skin Cancers Rapid Oral Abstract Session)
Data from a Phase III study independently conducted by Kelun-Biotech in China, evaluating sac-TMT versus chemotherapy for previously treated locally recurrent or metastatic TNBC (Abstract #104; Next-Generation Antibody–Drug Conjugates: The Revolution Continues Clinical Science Symposium Session)
Data from a Phase II study independently conducted by Kelun-Biotech in China was disclosed for the first time, evaluating sac-TMT in combination with KL-A167 (PD-L1 monoclonal antibody) for first-line treatment of advanced NSCLC (Abstract #8502; Lung Cancer—Non-Small Cell Metastatic Oral Abstract Session).
Phase II KeyVibe-005 Study B1 Cohort Data: Evaluation of Vibostolimab/Pembrolizumab in Previously Treated dMMR Endometrial Cancer Patients (Abstract #5502; Gynecologic Cancer Oral Abstract Session)
MSD Investor Event
MSD to Host Investor Event on June 3 at 6:00 PM (Central Time) During ASCO Annual Meeting to Share Company’s Oncology Strategy and Programs; Event to be Held in Chicago, U.S., with Live Webcast.
More key abstracts to be presented at the ASCO meeting include:
Image Source: MSD Official WeChat
Editor: Cottonwood
Disclaimer: This article is a reprint from Pharmacist Network. The images and text are the property of the original author, and the purpose of the reprint is to convey more information. It does not represent the views of this platform. If there are any issues regarding the content, copyright, or other aspects, please leave a message on this platform, and we will address it promptly.
